ClinicalTrials.gg
RecruitingNCT07526545UPRISEUpdated Oct 15, 2026

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

An interventional study of Biopsy Procedure and Diagnostic Procedure in Prostate Carcinoma, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to male participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Screening

How we know

Updated Oct 15, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center — 7 open to participants now, 12 under way, none of them phase 3. Prostatic Neoplasms · University of Michigan Rogel Cancer Center.

Planned enrollment
2nd of 33
800 · median 28
Started
2026
with 3 others
No phase
10 of 36
1 open now
Primary completion
2030-06
later than 10 of 11 live
Registered
34th of 36
by date

Among the 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center, this one is the 2nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2026, is one of 10 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 34th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 50 Years to 75 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center, or all of them as a file.
02

Study summary

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

03

Conditions studied

  • Prostate Carcinoma

Browse trials for

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males aged 50-75
  • PSA 3-20 ng/ml within the previous 3 months
  • Fit to undergo all procedures listed in protocol per treating physician's discretion
  • No prostate in the past 4 years
  • No prostate MRI in the past 2 years
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis of prostate cancer
  • to MRI (e.g. claustrophobia, pacemaker)
  • Contraindication to prostate
  • Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Arm I (MPS2)

    Patients undergo urine sample collection for MPS2 testing. Patients' treating physicians review and utilize the results of the MPS2 test to determine if patients undergo SOC MRI and/or biopsy.

    Procedure: Biopsy Procedure · Device: Diagnostic Procedure · Other: Electronic Health Record Review · Procedure: Magnetic Resonance Imaging

  • Active comparator
    Arm II (MPS2)

    Patients undergo urine sample collection for MPS2 testing. Patients' treating physicians do NOT review or utilize results of the MPS2 test to determine if patients undergo a biopsy after SOC MRI.

    Procedure: Biopsy Procedure · Device: Diagnostic Procedure · Other: Electronic Health Record Review · Procedure: Magnetic Resonance Imaging

Interventions

  • ProcedureBiopsy Procedure

    Undergo biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • DeviceDiagnostic Procedure

    Undergo MPS2 urine test

    Also known as: Diagnostic, Diagnostic Method, Diagnostic Technique, Diagnostic Test, Evaluation Basis of Disease Status

  • OtherElectronic Health Record Review

    Ancillary studies

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

06

What researchers measure

Primary outcomes

  1. Clinically significant prostate cancer (csPCa), defined as Gleason Grade (GG) Group 2-5

    Will compare the proportions of patients with detected csPCa in the intervention and control arms (p1 and p2, respectively) using the OBrien Fleming stopping boundaries which control the overall one-sided Type I error rate to be less than .10.

    Time frame: Up to 120 days

Secondary outcomes

  1. Number of biopsies performed

    Will be compared between arms using Farrington-Manning (score) tests for the difference in two independent proportions.

    Time frame: Up to 120 days

  2. Detection of GG1 cancers

    Will be compared between arms using Farrington-Manning (score) tests for the difference in two independent proportions.

    Time frame: Up to 120 days

  3. Number of multiparametric magnetic resonance imaging performed

    Will be compared between arms using Farrington-Manning (score) tests for the difference in two independent proportions.

    Time frame: Up to 120 days

  4. Adherence to the management recommendations in the biomarker-based arm

    Time frame: Up to 120 days

  5. My Prostate Score 2 (MPS2) performance for detecting csPCa

    The sensitivity and specificity of MPS2 will be calculated using the established threshold both for a population of all patients (assuming patients without a biopsy do not have csPCa) and separately for patients with Prostate Imaging Reporting and Data System 3-5 who undergo a biopsy.

    Time frame: Up to 120 days

  6. Cost

    Will be compared between arms using Wilcoxon Rank Sum Tests due to expected skewed distributions. These analyses will be conducted as a 2-sided .05 alpha level.

    Time frame: Up to 120 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2030, 42 months later.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 42 months is close to that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Sep 2026 → Dec 2026, primary completion Mar 2030 → Jun 2030 and completion Mar 2030 → Jun 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 13, 2026
StartEst.
Dec 1, 2026was Sep 2026
Primary completionEst.
Jun 1, 2030was Mar 2030
CompletionEst.
Jun 1, 2030was Mar 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
University of Michigan Rogel Cancer Center is now Recruiting
Oct 15, 2026
Start date
Sep 1, 2026→Dec 1, 2026
Oct 15, 2026
Primary completion
Mar 1, 2030→Jun 1, 2030
Oct 15, 2026
Study completion
Mar 1, 2030→Jun 1, 2030
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    University of Michigan Rogel Cancer Center is now Recruiting
    Start date Sep 1, 2026→Dec 1, 2026
    Primary completion Mar 1, 2030→Jun 1, 2030
    Study completion Mar 1, 2030→Jun 1, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07526545
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 1, 2030 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Uprise StudyTeam
Contact
uprise-spore@med.umich.edu
734-615-6662
Udit Singhal, MD
principal investigator · University of Michigan Rogel Cancer Center
Todd Morgan, MD
principal investigator · University of Michigan Rogel Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion